| Quote | Spy CBST NEW ![]() |
Message Board | |||||
|
Visit a stock's Spy page to see who else is tracking it and who else is talking about it. Spy pages also list institutional holders. |
|
Cubist Pharmaceuticals: A Drug Stock With Potential For Solid Gain
TEVA CBST Linked by The Razor's Edge - February 15, 02:55PM from (blog.ockhamresearch.com) It is clear that investors are getting much more solid fundamentals for their $20 per share investment than they were in more ...
Cubist Pharma Posts Q4 adj.-EPS of $0.68, Tops Views
CBST Linked by StreetInsider - January 21, 04:05PM from (www.streetinsider.com) more ...
Cubist Pharmaceuticals Completes Acquisition Of Calixa Therapeutics
CBST Linked by BusinessWire - December 16, 04:07PM from (www.businesswire.com) Cubist Pharmaceuticals, Inc., (NASDAQ: CBST) a leading acute care therapeutics company has completed its previously announced more ...
Cubist Pharmaceuticals to Acquire Calixa Therapeutics
CBST Linked by BusinessWire - December 14, 12:01AM from (www.businesswire.com) Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) a leading acute care therapeutics company, announced today the signing of a definitive more ...
Closing Bell: No economic help today (CBST, AMZN, ABK, BAC, HUN, DD, STEM, STI)
DD BAC STI ABK STEM CBST AMZN HUN Linked by BloggingStocks - December 03, 04:15PM from (www.bloggingstocks.com) The weekly jobless claims set the tone for a positive day, but the Obama speech comments today may have set the tone for more ...
Cubist Pharma upgraded to "outperform"
CBST Linked by newratings - December 03, 02:13PM from (www.newratings.com) NEW YORK, December 3 (newratings.com) - Analysts at RBC Capital Markets upgrade Cubist Pharmaceuticals (ticker: CBST) from more ...
Analyst upgrades, downgrades and initiations: AAPL, AMZN, BAC, DRYS, GENZ, REG, S ...
BDX KMT BAC S AAPL GENZ GIII KIM TCK ENB REG CBST AVB AMZN CTSH DRYS TX Linked by BloggingStocks - December 03, 11:40AM from (www.bloggingstocks.com) Analyst Upgrades FBR Capital upgraded Bank of America (BAC) to outperform from market perform to reflect more ...
Cubist Pharmaceuticals Closes Enrollment Early in CONSERV™-1 and CONSERV-2 Ph. 2 Trials for CB-500,929 (Ecallantide), in Development as Therapy to Reduce Bleeding in On-Pump Cardiac Surgery
CBST Linked by BusinessWire - December 03, 07:14AM from (www.businesswire.com) Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the early closing of enrollment in its ecallantide Phase 2 program. more ...
Top 10 Analyst Upgrades, Downgrades, and Initiations
BAC AAPL CELG POT CBST AMZN EBAY RIG AGO DRYS Linked by 24/7 Wall St. - November 29, 07:00PM from (247wallst.com) These are this morning's top analyst upgrades, downgrades, and initiations seen from Wall Street research calls: Amazon.com more ...
Hydra Biosciences and Cubist Form Collaboration to Develop Novel Ion Channel Drugs for Pain Management
CBST Linked by BusinessWire - October 19, 08:30AM from (www.businesswire.com) Hydra Biosciences today announced that they have entered into an agreement with Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) more ...
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Home | About | Register | My tickerspy | Logout | Web site design by LightMix |
| © 2010 Indie Research, LLC. All rights reserved. | |
---
Institutional Holdings Disclaimer Pro portfolios track the top 15 quarterly holdings of more than 1,400 institutions. Comments in Pro portfolios show the institution's change in shares held for each company quarter over quarter. Pro portfolio performance is based on institutions' top 15 holdings as disclosed in quarter-end filings with the SEC. Pro performance does not take into account additional holdings beyond the top 15 nor does it include positions that are not required to be disclosed by the SEC. As such, Pro portfolio performance should be considered an approximation and not a precise record of how an institution has performed over time. tickerspy is not affiliated with any of the Pro investors profiled on our web site. The performance data and graph are estimates and do not represent an advertisement or endorsement by either tickerspy or the Pro investors. THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED "AS IS" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, INDIE RESEARCH, LLC AND IT LICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS AND NON-INFRINGEMENT. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER INDIE RESEARCH, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICNESORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGAES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.
|
|